Search results
Results from the WOW.Com Content Network
2C-B (4-bromo-2,5-dimethoxyphenethylamine), also known as Nexus, is a synthetic psychedelic drug of the 2C family, mainly used as a recreational drug. [2] [1] [4] It was first synthesized by Alexander Shulgin in 1974 for use in psychotherapy.
There are two known subtypes of cannabinoid receptors, termed CB 1 and CB 2. [6] [7] The CB 1 receptor is expressed mainly in the brain (central nervous system or "CNS"), but also in the lungs, liver and kidneys. The CB 2 receptor is expressed mainly in the immune system, in hematopoietic cells, [8] and in parts of the brain. [9] The protein ...
Another endocannabinoid, 2-arachidonoylglycerol, binds to both the CB 1 and CB 2 receptors with similar affinity, acting as a full agonist at both. [ 76 ] 2-AG is present at significantly higher concentrations in the brain than anandamide, [ 81 ] and there is some controversy over whether 2-AG rather than anandamide is chiefly responsible for ...
These effects are common for most psychedelics in the substituted phenethylamine class. There is a strong similarity between the subjective effects caused by βk-2C-B and 2C-B. However, βk-2C-B is often described to be more stimulating and less psychedelic. This, combined with its long duration, could increase the perceived severity of the ...
The cannabinoid receptor 2 (CB2), is a G protein-coupled receptor from the cannabinoid receptor family that in humans is encoded by the CNR2 gene. [5] [6] It is closely related to the cannabinoid receptor 1 (CB1), which is largely responsible for the efficacy of endocannabinoid-mediated presynaptic-inhibition, the psychoactive properties of tetrahydrocannabinol (THC), the active agent in ...
For example, Δ 9-THC has an EC 50 of 250 nM at CB 1 and 1157 nM at CB 2, whereas PB-22 has an EC 50 of 5.1 nM at CB 1 and 37 nM at CB 2. [8] Adverse effects observed due to synthetic cannabinoid use include acute kidney injury , cardiac toxicity , seizure , stroke , tremor , hypokalemia , and rhabdomyolysis .
3D model of 2-Arachidonoylglycerol, an endocannaboid. The endocannabinoid system (ECS) is a biological system composed of endocannabinoids, which are neurotransmitters that bind to cannabinoid receptors, and cannabinoid receptor proteins that are expressed throughout the central nervous system (including the brain) and peripheral nervous system.
[14] [15] CB 1 receptors are present in highest concentration in the brain but can also be found in the periphery. CB 2 receptors are mostly located in the immune and haematopoietic systems. [1] [14] Endocannabinoids are eicosanoids acting as agonists for cannabinoid receptors, and they occur naturally in the body. [9]